Cantel Medical Corp. (CMD) Earning Somewhat Positive News Coverage, Report Shows

Media stories about Cantel Medical Corp. (NYSE:CMD) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cantel Medical Corp. earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.0966896869628 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

Cantel Medical Corp. (NYSE:CMD) opened at 73.79 on Friday. The firm’s 50-day moving average is $75.90 and its 200 day moving average is $76.88. The firm has a market capitalization of $3.06 billion, a P/E ratio of 43.66 and a beta of 1.23. Cantel Medical Corp. has a 52-week low of $68.19 and a 52-week high of $88.81.

Cantel Medical Corp. (NYSE:CMD) last issued its quarterly earnings results on Thursday, June 8th. The company reported $0.51 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.51. Cantel Medical Corp. had a net margin of 9.50% and a return on equity of 17.75%. The firm had revenue of $192.10 million for the quarter, compared to analyst estimates of $193.84 million. Cantel Medical Corp.’s revenue was up 10.6% compared to the same quarter last year. Equities analysts anticipate that Cantel Medical Corp. will post $2.06 EPS for the current year.

The firm also recently declared a semiannual dividend, which was paid on Monday, July 31st. Shareholders of record on Monday, July 17th were paid a $0.07 dividend. The ex-dividend date of this dividend was Thursday, July 13th. This represents a yield of 0.18%. Cantel Medical Corp.’s payout ratio is currently 8.28%.

A number of research firms have recently weighed in on CMD. Zacks Investment Research raised shares of Cantel Medical Corp. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Sidoti raised shares of Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price target on the stock in a research note on Wednesday, August 2nd. Benchmark Co. downgraded shares of Cantel Medical Corp. from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cantel Medical Corp. in a research note on Thursday, June 8th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $91.67.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://transcriptdaily.com/2017/08/13/cantel-medical-corp-cmd-given-daily-media-impact-rating-of-0-09-updated-updated.html.

In other Cantel Medical Corp. news, Chairman Charles M. Diker sold 13,000 shares of Cantel Medical Corp. stock in a transaction on Monday, June 12th. The shares were sold at an average price of $76.36, for a total value of $992,680.00. Following the sale, the chairman now directly owns 3,124,222 shares in the company, valued at approximately $238,565,591.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Charles M. Diker sold 35,000 shares of Cantel Medical Corp. stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $75.52, for a total transaction of $2,643,200.00. Following the completion of the sale, the chairman now owns 3,114,520 shares in the company, valued at $235,208,550.40. The disclosure for this sale can be found here. 14.90% of the stock is currently owned by insiders.

Cantel Medical Corp. Company Profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply